PubMed

Immunohistochemical characterization of subtypes of male breast carcinoma.

Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M.

Breast Cancer Res. 2009;11(3):R28. Epub 2009 May 14.PMID: 19442295 [PubMed - indexed for MEDLINE]Related articlesFree article

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.PMID: 16757721 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.

Hum Pathol. 2006 Sep;37(9):1217-26. Epub 2006 Jul 18.PMID: 16938528 [PubMed - indexed for MEDLINE]Related articles

Identification of a basal-like subtype of breast ductal carcinoma in situ.

Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.

Hum Pathol. 2007 Feb;38(2):197-204.PMID: 17234468 [PubMed - indexed for MEDLINE]Related articles

Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia.

Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1807-14.PMID: 19505913 [PubMed - indexed for MEDLINE]Related articles

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM.

Mod Pathol. 2006 Feb;19(2):264-71.PMID: 16341146 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.PMID: 17950079 [PubMed - indexed for MEDLINE]Related articles

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC.

Breast Cancer Res. 2008;10(4):R67. Epub 2008 Aug 5.PMID: 18681955 [PubMed - indexed for MEDLINE]Related articlesFree article

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6.PMID: 18261623 [PubMed - indexed for MEDLINE]Related articles

Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer.

Bryan BB, Schnitt SJ, Collins LC.

Mod Pathol. 2006 May;19(5):617-21.PMID: 16528377 [PubMed - indexed for MEDLINE]Related articlesFree article

Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Biswas DK, Iglehart JD.

J Cell Physiol. 2006 Dec;209(3):645-52. Review.PMID: 17001676 [PubMed - indexed for MEDLINE]Related articles

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.PMID: 17438091 [PubMed - indexed for MEDLINE]Related articlesFree article

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.

Steinman S, Wang J, Bourne P, Yang Q, Tang P.

Ann Clin Lab Sci. 2007 Spring;37(2):127-34.PMID: 17522367 [PubMed - indexed for MEDLINE]Related articles

Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.

Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F.

Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52. Epub 2008 Sep 2.PMID: 18768247 [PubMed - indexed for MEDLINE]Related articles

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.

Mohammadizadeh F, Naimi A, Rajabi P, Ghasemibasir H, Eftekhari A.

Indian J Med Sci. 2009 Apr;63(4):152-62.PMID: 19414985 [PubMed - indexed for MEDLINE]Related articlesFree article

Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.

Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY.

Oncol Rep. 2005 Aug;14(2):337-43.PMID: 16012712 [PubMed - indexed for MEDLINE]Related articles

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO.

J Natl Cancer Inst. 2009 May 20;101(10):736-50. Epub 2009 May 12.PMID: 19436038 [PubMed - indexed for MEDLINE]Related articlesFree article

NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.

Van Laere SJ, Van der Auwera I, Van den Eynden GG, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY.

Br J Cancer. 2007 Sep 3;97(5):659-69. Epub 2007 Aug 14.PMID: 17700572 [PubMed - indexed for MEDLINE]Related articlesFree article

Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ.

Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, Quinn A, Hajdu S.

Ann Clin Lab Sci. 2006 Spring;36(2):137-43.PMID: 16682508 [PubMed - indexed for MEDLINE]Related articles

The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer.

Yu KD, Shen ZZ, Shao ZM.

Breast Cancer Res Treat. 2009 Dec;118(3):661-3. No abstract available. PMID: 19714461 [PubMed - indexed for MEDLINE]Related articles